Literature DB >> 30680974

[Pattern of biological changes in interstitial lung diseases].

F Gester1, B Duysinx1, C Von Frenckell2, R Louis1, J Guiot1.   

Abstract

Interstitial lung diseases (ILD) are a part of a vast and heterogeneous clinicopathological entity. The work-up have to rule out a granulomatosis or a secondary cause, before making the diagnosis of an idiopathic ILD. The etiological diagnosis is based on a multidisciplinary approach integrating a network of clinical and paraclinical datas. If the diagnosis remains unclear, a lung biopsy is suggested with a transbronchial approach (mainly cryobiopsy) or with a surgical approach (video-assisted thoracoscopy). This review article mainly describes the biological analyses that contribute to explore ILDs.

Entities:  

Keywords:  Autoantibodies ; Lung biopsy ; Pulmonary Fibrosis; Interstitial lung disease

Mesh:

Substances:

Year:  2019        PMID: 30680974

Source DB:  PubMed          Journal:  Rev Med Liege        ISSN: 0370-629X


  3 in total

1.  Inflammatory profile of induced sputum composition in systemic sclerosis and comparison with healthy volunteers.

Authors:  P Jacquerie; M Henket; B André; C Moermans; D de Seny; F Gester; R Louis; M Malaise; J Guiot
Journal:  Sci Rep       Date:  2021-05-21       Impact factor: 4.379

Review 2.  Biomarkers in systemic sclerosis-associated interstitial lung disease: review of the literature.

Authors:  Olivier Bonhomme; Béatrice André; Fanny Gester; Dominique de Seny; Catherine Moermans; Ingrid Struman; Renaud Louis; Michel Malaise; Julien Guiot
Journal:  Rheumatology (Oxford)       Date:  2019-09-01       Impact factor: 7.580

3.  A new nucleosomic-based model to identify and diagnose SSc-ILD.

Authors:  Julien Guiot; Monique Henket; Béatrice Andre; Marielle Herzog; Nathalie Hardat; Makon-Sebastien Njock; Catherine Moermans; Michel Malaise; Renaud Louis
Journal:  Clin Epigenetics       Date:  2020-08-17       Impact factor: 6.551

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.